AM-1221

AM-1221 is a synthetic cannabinoid research compound from the naphthoylindole family. It differs from AM-1220 by a methyl and nitro substitution on the indole ring, and it is best known for its strong selectivity toward the CB₂ cannabinoid receptor. Unlike many synthetic cannabinoids developed for recreational markets, AM-1221 has primarily been studied as a selective pharmacological tool.

Chemistry and relationship to AM-1220

AM-1221 is 1-[(N-methylpiperidin-2-yl)methyl]-2-methyl-3-(naphthalen-1-oyl)-6-nitroindole. It shares the naphthoylindole and methylpiperidinylmethyl features of AM-1220, but has additional methyl and nitro substituents on the indole core. These changes are associated with a substantially different receptor-selectivity profile.

The FDA Substance Registration System records AM-1221 as a distinct chemical substance and lists its CAS number and structural identity (FDA Substance Registration System: AM-1221).

Pharmacology

AM-1221 is described as a highly selective CB₂ receptor agonist. Published binding data report a K_i of approximately 0.28 nM at CB₂ and 52.3 nM at CB₁, indicating a marked preference for the peripheral receptor subtype. This profile distinguishes it from many recreational synthetic cannabinoids that are designed or selected for strong central CB₁ activity (Emerging drugs of abuse: current perspectives on synthetic cannabinoids, 2015).

CB₂ receptors are expressed prominently in immune and peripheral tissues and have been investigated in pain and inflammatory pathways. Selective CB₂ agonism does not imply the same intoxicating effects as strong CB₁ activation.

Effects in experimental research

AM-1221 has been used as a pharmacological tool in studies examining CB₂-mediated signalling and analgesia. Its receptor selectivity makes it useful for separating peripheral CB₂ effects from central CB₁-mediated responses in experimental models.

Neither a substantial body of human accounts nor a controlled clinical trial establishes its subjective effects. Its classification alone therefore gives no basis for describing AM-1221 as a conventional cannabis-like recreational drug.

Toxicity and research limitations

Human toxicology data for AM-1221 are very limited. Its acute toxic range, metabolism, dependence potential and long-term effects have not been adequately characterised in people. The available pharmacology is based primarily on receptor-binding and preclinical research.

AM-1221 should not be confused with AM-1220. Despite their similar names and shared naphthoylindole scaffold, AM-1221 is strongly CB₂-selective, while AM-1220 has a more pronounced CB₁ profile.

Related compounds

AM-1221 is related to AM-1220, AM-1241 and other experimental CB₂-selective cannabinoid ligands. Its nitro-substituted indole structure distinguishes it from the unsubstituted AM-1220 scaffold.